# The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer

> **NCT00440128** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Nausea and Vomiting, Chemotherapy-Induced

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Casopitant/Docetaxel

## Key facts

- **NCT ID:** NCT00440128
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-04
- **Primary completion:** 2008-07-17
- **Final completion:** 2008-07-17
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440128, "The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00440128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*